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Total Chemical Synthesis of Lassomycin and Lassomycin-amide  
S. Lear,
a
 T. Munshi,
b
 A. S. Hudson,
a
 C. Hatton,
a
 J. Clardy,
c
 J. A. Mosely,
a
 T. J. Bull,
b
 C. S. Sit,
c,
* and S. 
L. Cobb
a,
*
 
Herein we report a practical synthetic route to the lasso peptide lassomycin (1) and C-terminal variant lassomycin-amide 
(2). The biological evaluation of peptides 1 and 2 against Mycobacterium tuberculosis revealed that neither had any 
activity against this bacterium. This lack of biological activity has led us to propose that naturally occurring 
lassomycin may actually exhibit a standard lasso peptide threaded conformation rather than the previously 
reported unthreaded structure.  
Introduction 
The pressing issue of antimicrobial resistance continues to 
drive the search for novel antibiotic scaffolds.
1
 Emerging 
threats such as extensively drug-resistant tuberculosis require 
the use of innovative approaches in the search for potential 
leads.
2,3 
Lassomycin (1), a natural product belonging to the 
‘lasso’ peptide class, was recently isolated from an 
Actinomycete (Lentzea kentuckyensis sp.) in a screen of a 
library of previously uncultured soil bacteria.
4
 The lasso 
peptide was found to possess potent and specific bactericidal 
activity against mycobacteria, including drug-resistant forms of 
Mycobacterium tuberculosis. The specificity of activity arises 
due to the fact that lassomycin targets the ClpC1 ATPase, an 
essential enzyme in mycobacteria. ClpC1 ATPase is a key 
component of protein degradation together with the ClpP1P2 
proteolytic complex.
5 
The previously reported solution-state NMR structure of 
lassomycin is shown in Fig. 1. The peptide does not adopt the 
characteristic knot conformation reported for other 
homologous lasso peptides: here the C-terminus packs tightly 
against the N-terminal ring instead of passing through the 
macrolactam.
4
 In light of this discovery, and the potential of 
lasso peptides as novel drug scaffolds in general,
6-8
 we set out 
to chemically synthesize the natural product. 
Herein, we report the first chemical synthesis of the 
recently identified lasso-peptide lassomycin (1) and a C-
terminal amide derivative, lassomycin-amide (2). Synthetic 
peptides 1 and 2 were also evaluated for activity against M. 
tuberculosis. 
 
Fig. 1 Amino acid sequence and proposed solution-state NMR structure of lassomycin 
(1).
4,9
 The N- and C-terminus are labelled. 
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Results and Discussion  
 
Two key structural features that need to be incorporated 
during a chemical synthesis of lassomycin (1) are the 
isopeptide bond formed between the N-terminus and the 
carboxylate side chain of Asp-8, and the methylated C-
terminus (Fig. 1). We envisaged two possible synthetic 
approaches to access lassomycin (1) and these are outlined in 
Scheme 1. Route A involved the preparation of a linear peptide 
and the formation of the lactam ring on resin using an allyl 
ester orthogonal protecting group strategy for the side chain 
of Asp-8. The C-terminal methyl ester would be installed using 
2-chlorotrityl chloride resin and the approach reported by 
Turner et al. (Scheme 1, Route A).
10
 The alternative approach 
(Scheme 1, Route B), involved assembling the linear peptide on 
resin via side chain anchoring. In this approach a di-peptide 
fragment would be loaded initially onto the resin allowing the 
C-terminal methyl ester functionality to be installed at this 
point. Lactam ring formation would be carried out in solution. 
Initially, Route A (Scheme 1) was investigated and the 
linear peptide 7 was successfully assembled via standard Fmoc 
solid phase peptide synthesis (SPPS). Next, we attempted the 
on-resin deprotection of the Asp-8 side chain. In our hands all 
attempts to remove the allyl ester and generate peptide 6 
were unsuccessful, despite the use of stoichiometric amounts 
of tetrakis(triphenylphosphine)palladium(0) catalyst and 
triphenylsilane, and trialling a number of reaction solvents. 
The lack of success in allyl ester removal was assumed to arise 
from a difficulty in coordinating the allyl moiety to the catalyst, 
presumably due to steric hindrance around the metal centre. 
This effect will depend upon peptide sequence length and 
folding of the peptide, and as such is likely to be highly 
sequence dependent. In light of these difficulties alternative 
orthogonal protecting groups were considered (i.e. highly acid 
sensitive,
11
 photolabile
12
 or silicon-based
13
 protection), 
however the requirement for more specialized deprotection 
conditions, or the lack of available commercial building blocks, 
led us to investigate Route B (Scheme 1). 
The synthesis of the required orthogonally protected di-
peptide (10) for Route B was carried out in solution. Removal 
of the t-butyl side chain from 10 under standard acidic 
conditions followed by attachment to Rink amide resin gave 
the methyl ester protected C-terminal fragment of lassomycin 
(Scheme 2). The peptide chain was then extended on resin 
using Fmoc SPPS to give a complete linear version of 
lassomycin (12). Cleavage from the resin afforded the linear 
peptide (3) which was ready for lactam ring formation. 
While peptide macrocyclizations are often best performed 
under high dilution to minimize unwanted oligomer 
formation,
14
 the ‘pseudo-high dilution’ conditions described by 
Malesevic et al. were instead utilized as a more convenient 
alternative in order to minimize solvent usage.
15
 11.3 mL each 
of solutions of peptide 3 (0.01 M) and HATU (0.03 M) in DMF 
were added to a reaction flask containing DIPEA and HOAt 
over a period of ~20 h at a rate of 0.01 mL/min (syringe pump 
controlled). Slow addition was used in order to keep the 
effective reaction concentration low, while requiring only a 
relatively small final solvent volume (34 mL). Removal of the 
solvent under vacuum and HPLC purification of the crude 
reaction product yielded lassomycin (1) in high purity, as 
confirmed by analytical HPLC and MALDI-TOF MS (Fig. 2). 
Scheme 1 Proposed synthesis routes to lassomycin (1): A) on resin cyclization and B) combined solution/on-resin approach (amino acid side chain protecting groups are 
omitted for clarity).
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Fig. 2 HPLC trace (left) and MALDI-TOF mass spectrum (right) for synthetic lassomycin 
(1). HPLC absorbance recorded at 220 nm, gradient 0-100% B over 30 min (A = 
5:95:0.05 MeCN/H2O/TFA; B = 95:5:0.03 MeCN/H2O/TFA). 
MALDI LIFT-TOF/TOF
16
 MS/MS was used to confirm the correct 
sequence for the linear tail portion of lassomycin (Supporting 
Information). However, fragmentation was not observed for 
the cyclic region, but this matched the data reported by 
Gavrish et al. from MS/MS sequencing of the isolated natural 
lassomycin.
4
 A complete set of fragment ions were observed 
for the uncyclized peptide. 
Ion mobility (IM) mass spectrometry was also carried out 
on the synthetic peptide. A number of peaks with distinct 
collisional cross sections were resolved belonging to either 
lassomycin or a trace amount of the C-terminal acid hydrolysis 
product (14) (Supporting Information, SI Figure 7). Only a 
single peak was observed for each species suggesting that only 
one conformation is present, as opposed to distinct 
populations of threaded and unthreaded peptide (or that the 
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Scheme 2 Synthesis of lassomycin. The dipeptide Fmoc-Asp(OH)-Ile-OMe (13) was  prepared in solution and anchored to Rink amide resin via the Asp side chain. The 
required sequence was then elongated via SPPS, before global deprotection and cleavage from the resin. Cyclization of the linear peptide in solution yielded the 
cyclic target. Reagents and conditions: (i) PyBOP® (1.0 equiv) and NMM (3.0 equiv), DCM, rt, 18 h; SiO2, 98/2% hexane/EtOAc → 50/50% hexane/EtOAc, 63%; (ii) 
40% TFA, DCM, rt, 30 min, 100%; (iii) Rink amide resin (0.79 mmol/g), Fmoc-Asp(OH)-Ile-OMe (13) (3.1 equiv), PyBOP® (3.1 equiv) and DIPEA (6.2 equiv), DMF, RT, 2 
× 1 h; (iv) Fmoc SPPS (see Experimental section); (v) TFA (95%, water), TIPS, rt, 4 h; (vi) HATU (3.0 equiv) and DIPEA (6.0 equiv), DMF, rt, 20 h (pseudo-high dilution, 
see text), 14%.
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collisional cross section for threaded/unthreaded ions is 
identical). 
It was also possible to access lassomycin-amide (2) a C-
terminal amide version of the original lassomycin (1) peptide. 
Synthesis of the required linear peptide (15) was carried out 
on Rink Amide resin using Fmoc SPPS, and cleavage from the 
resin afforded peptide 16 (Scheme 3). Formation of the lactam 
ring in solution and HPLC purification to yield lassomycin-
amide (2) were carried out as previously described for the 
synthesis of 1. Purity and structure were confirmed by 
analytical HPLC (Supporting Information, SI Figure 2), MALDI-
TOF MS (Supporting Information, SI Figure 2) and tandem mass 
spectrometry (Supporting Information, SI Figure 1). 
Peptides 1 and 2, as well as truncated analogue 
lassomycin(1-9) (17) representing the peptide without the tail 
were tested against Mycobacterium tuberculosis H37Rv in MIC 
assays utilizing both solid-agar based and liquid-media based 
methods. None of the peptides showed inhibitory activity 
when tested, up to concentrations of 100 μg/mL. These results 
were surprising in particular for peptide 1, given the previously 
reported biological activity profile.
4
 Given the unlikely nature 
of spontaneous threading during the synthesis of 1 (and 2) it is 
logical to assume that the peptides reported herein are un-
threaded. This, in combination with the biological data, leads 
us to speculate that the un-threaded structure previously 
reported may not be correct. 
The structural discrepancy from the original report
4
 could 
possibly be due to instability of lassomycin in its threaded 
conformation. Several examples have been documented of 
lasso peptides unthreading upon heat treatment. Caulosegnin I 
unthreads completely after 4 hours at 95 °C, while caulosegnin 
III unthreads and decomposes at elevated temperatures.
17
 
Similarly, astexin-1 unthreads when heated to 50 °C for 4 
hours
18
 and astexin-2 unthreads and decomposes after heating 
at 95 °C for 2 hours.
19
 In contrast, caulosegnin II and astexin-3 
show minimal to no unthreading when heated at 95 °C for 
prolonged periods of time.
17,19
 
In order to further elucidate the effect of temperature on 
the conformational state of lassomycin, structural 
characterization of synthetic peptide 1 was carried out using 
two-dimensional NMR. A comparison of 
1
H–
13
C HSQC spectra 
for 1 at two different temperatures is shown in Fig. 3. The 
NMR data gatherered is also compared in Fig. 3 with the 
naturally isolated labelled [
13
C, 
15
N]lassomycin.
4
 No noticeable 
changes in chemical shift values are observed between the 
spectrum of 1 at 25 °C and at 40 °C. Furthermore, clear 
differences in the 
1
H–
13
C HSQC spectrum can be seen between 
the synthetic peptide (1) and the naturally isolated lassomycin 
at 40 
o
C (Fig. 3). These results strongly suggest that the 
conformation of 1 does not change appreciably upon heating, 
and they highlight that there are significant differences 
between the conformation of synthetically prepared 
lassomycin (1) and that of naturally isolated lassomycin.
4
 
N
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H2N-GLRRLFADQLVGRRNI
Trt
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Pbf
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Pbf
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O
H2N-GLRRLFADQLVGRRNI
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O
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i
Scheme 3 Synthesis of lassomycin-amide (2). The peptide sequence was synthesized 
via SPPS on Rink amide resin (0.79 mmol/g), before global deprotection and cleavage 
from the resin. Cyclization of the linear peptide in solution yielded the cyclic target. 
Reagents and conditions: (i) TFA (95%, water), TIPS, rt, 4 h; (ii) HATU (3.0 equiv) and 
DIPEA (6.0 equiv), DMF, rt, 20 h (pseudo-high dilution, see text), 8%.  
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In light of this evidence, we propose that synthetic 
lassomycin (1) either exists in the unconstrained unthreaded 
form, or as a threaded lasso, but that there is no 
interconversion between these structures at temperatures 
upto 40 °C. Given the clear differences observed in the NMR 
between the synthetic and naturally isolated lassomycin, it 
seems likely that one peptide is threaded while the other is 
not. This idea of two distinct conformations being adopted by 
the synthetic and natural peptides is supported further by the 
biological data obtained where clear differences in activity are 
seen.  
We propose that i) neither peptide has undergone 
unthreading (or threading) upon heating during NMR data 
collection, or ii) one peptide has undergone threading from an 
initial unthreaded state whilst the other has undergone 
unthreading. For case ii) the peptide undergoing unthreading 
cannot be the naturally isolated lassomycin, as this would 
imply that the synthetic peptide (1) has undergone threading 
and that it is threaded at the point of NMR data collection, 
thus paradoxically implying (given the NMR study of 
temperature dependence already discussed) that a threaded 
lassomycin cannot unthread. Neither scenario therefore 
supports the hypothesis that the naturally isolated lassomycin 
has undergone unthreading upon heating to 40 °C. 
Furthermore, given the unlikely nature of scenario ii), taken 
together with the previously dicussed likelihood that synthetic 
lassomycin is in fact unthreaded, we propose that the 
previously published naturally isolated lassomycin actually 
exists as a threaded lasso that does not unthread upon heating 
to 40 °C. 
Conclusions 
We have developed a practical synthetic route to an 
unthreaded version of the lasso peptide lassomycin (1). 
Lassomycin-amide (2), a C-terminal amide derivative of 1 was 
also prepared. The biological evaluation of peptides 1 and 2 
against Mycobacterium tuberculosis revealed that neither had 
any activity. A lack of biological activity and our NMR analysis 
of synthetic lassomycin (1) suggest that naturally occurring 
lassomycin exhibits a standard lasso peptide threaded 
conformation rather than the reported unthreaded structure. 
Further conformational studies to gain additional insight in this 
area are ongoing.  
Experimental 
All reagents were purchased from Sigma-Aldrich unless 
otherwise specified. Peptide synthesis grade DMF was 
purchased from AGTC Bioproducts (Hessle, UK) and amino acid 
derivatives were purchased from CEM, Novabiochem (Merck) 
or AGTC. PyBOP® was purchased from Apollo Scientific 
(Stockport, UK). All resins were purchased from Novabiochem. 
Peptide molecular weight calculations and mass assignments 
were carried out using Pep-Calc.com.
20
 
 
Peptide synthesis 
Automated SPPS was carried out at 0.10 mmol scale on a CEM 
Liberty1 single-channel microwave peptide synthesizer 
equipped with a Discover microwave unit. All reactions were 
carried out at room temperature in DMF using 2 × 1 h 
couplings for all residues except Arg, which was triple coupled 
(3 × 1 h). Fmoc-protected amino acids were used (5 equiv), 
with PyBOP® (5 equiv) as the activator in the presence of 
DIPEA (10 equiv, 2 M solution in NMP). Amino acid side chain 
functionality was protected as follows: Fmoc-His(Trt)-OH, 
Fmoc-Ser(OtBu)-OH and Fmoc-Thr(OtBu)-OH. The Fmoc group 
was removed by two successive treatments with 20% (v/v) 
piperidine solution in DMF (5 + 10 min). An additional 10 min 
Fig. 3 Overlay of expanded regions of 
1
H–
13
C HSQC (heteronuclear single-quantum correlation) NMR spectra of naturally isolated [
13
C, 
15
N]lassomycin at 40 °C (green), 
and synthetic lassomycin (1) at 25 °C (blue) and 40 °C (red). Clear differences in chemical shift values at 40 °C are observed between 1 and the natural isolate. In 
contrast, shift values for the synthetic peptide (1) do not change noticeably over the temperature range surveyed. (Full spectra given in the Supporting Information.) 
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deprotection was carried out for the penultimate residue (Leu-
2). Bubbling with nitrogen gas was used to ensure efficient 
agitation of the reaction mixture during each step. Preswelling 
of dry resin was carried out in DMF for a minimum of 1 h. 
 
Cleavage from solid support 
Peptide-resin was shrunk in diethyl ether and treated with 
2.85 mL TFA, 0.15 mL deionized water and 0.15 mL TIPS for 4 h 
at room temperature. The resin was then removed by filtration 
and the filtrate concentrated in vacuo before precipitation 
using ether and decanting of the liquid (followed by 
subsequent ether washes). The resulting solid peptide was 
dissolved in deionized water containing 0.1% TFA and 
lyophilized. 
 
Solution-phase cyclization 
The cyclization was carried out using the pseudo-high dilution 
conditions described by Malesevic et al.
15
 Fully deprotected 
peptide (113 μmol) and HATU (339 μmol) were dissolved 
separately in 11.3 mL each of DMF which had been dried over 
molecular sieves. Both solutions were added simultaneously 
using two syringe pumps at a rate of 0.01 mL/min each to a 
stirred solution of HATU (11.3 μmol) and DIPEA (678 μmol) in 
dry DMF (11.3 mL) over a period of ~20 h. After the addition 
was complete, the reaction was stirred for a further 30 min 
and the solvent was removed under vaccum. The resulting oil 
was kept at -20 °C until needed for purification. 
 
High-performance liquid chromatography 
The crude cyclization reaction product was dissolved in 2.5 mL 
deionized water/acetonitrile, filtered, centrifuged and injected 
in 0.5 mL amounts (per run) onto a Speck and Burke Analytical 
C18 Column (5.0 μm, 10.0 × 250 mm) attached to a 
PerkinElmer Series 200 LC Pump and 785A UV/Vis Detector. A 
linear gradient of 10-36% B (solvent A = 5:95:0.1 
MeCN/H2O/TFA; B = 95:5:0.1 MeCN/H2O/TFA) over 40 min, 
followed by 36-100% B over 20 min, with a flow rate of 2 
mL/min was used for separations. Absorbance data were 
collected at 220 nm. Selected fractions were lyophilized and a 
mass assigned using MALDI-TOF MS or ESI-MS, and peak 
fractions of interest were pooled and lyophilized. 
 
Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were collected using a Varian VNMRS 700 MHz. 
Multiplicities: s = singlet, d = doublet, dd = doublet of doublets, 
m = multiplet, t = triplet. Chemical shifts are reported in δ units 
and are referenced to residual solvent peaks: CHCl3 (
1
H 7.26 
ppm, 
13
C 77.0 ppm) and DMSO (
1
H 2.50 ppm, 
13
C 39.5 ppm). 
 
Analytical liquid chromatography mass spectrometry (LCMS) 
Analytical LCMS was carried out using an Acquity UPLC system 
(Waters Ltd, UK) equipped with a photodiode array detector. 
Samples were injected onto an Acquity UPLC BEH C18 column 
(1.7 μm, 2.1 × 50 mm) and a gradient of 5–95% B (solvent A = 
H2O, 0.1% formic acid; B = MeCN) was run over 3.8 min with a 
flow rate of 0.6 mL/min. The flow of solvent from the UPLC 
system was introduced into the electrospray ion source of an 
Aquity TQD or QToF Premier mass spectrometer, and positive 
ions were measured. 
 
Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) 
MALDI-TOF mass data was collected using an Autoflex II 
ToF/ToF mass spectrometer (Bruker Daltonik GmBH) equipped 
with a 337 nm nitrogen laser. Peptides were dissolved in 1:1 
deionized water/MeCN for MS analysis. Sample solution (1 
mg/mL) was mixed with matrix solution (cyano-4-
hydroxycinnamic acid, ~50 mg/mL) in a ratio of 1:9, and 1 μL of 
the resulting solution spotted onto a metal target and placed 
into the MALDI ion source. MS data was processed using 
FlexAnalysis 2.0 (Bruker Daltonik GmBH). MALDI MS/MS was 
performed using LIFT technology, which enables detection of 
product ions that result from elevating the laser power. 
 
Ion-mobility (IM) mass spectrometry 
Ion-mobility mass spectrometry was carried out using a Synapt 
G2S mass spectrometer equipped with an Acquity UPLC 
(Waters Ltd, UK). 1 μL of sample was injected onto a BEH C18 
column (1.7 μm, 2.1 × 100 mm) and a gradient of 5–95% B 
(solvent A = H2O, 0.1% formic acid; B = MeCN, 0.1% formic 
acid) was run over 6.0 min with a flow rate of 0.4 mL/min. A 
photodiode array detector provided absorbance data from 200 
nm to 500 nm. The solvent flow was introduced into the 
electrospray ion source, and full scan MS carried out for 
positive ions. IM separation was performed with nitrogen as 
the gas. MS and photodiode array absorbance data was 
processed using MassLynx 4.1 (Waters Ltd, UK). IM results are 
represented as a plot of m/z against drift time in Bins 
(mobiliogram). 
 
MIC testing of compounds against mycobacteria 
The MICs of the compounds were determined using standard 
liquid-broth and solid-agar based methods. Briefly, serial 
dilutions of each compound were made between 100 mg/L 
and 0.78 mg/L with MB7H9/OADC (BD Biosciences) media in 
96-well U-bottom plates. Mycobacterium tuberculosis H37Rv 
was grown to log phase (OD600 = 1.0) and 10
4
 cells were added 
to all wells. Solid-agar based method was carried out as 
previously described
21
 using a 48-well plate format. 
Compounds (see above) were tested in triplicate by adding 
serial dilutions into separate wells overlaid with 
MB7H11/OADC (BD Biosciences) agar based media. 
Mycobacterium tuberculosis culture (5 µL containing 10
4
 cells) 
was then inoculated into the centre of each well on top of the 
solidified media. Plates were sealed and incubated at 37 °C in 
5% CO2 for 10 days. Each plate also contained standardised 
serial dilution controls of first line TB drugs isoniazid (INH 
[Sigma, UK]; concentration range 8, 4, 2, 1, 0.5, 0.25, 0.125, 
0.0625 µg/mL) and rifampicin (RIF [Sigma, UK]; concentration 
range 16, 8, 4, 2, 1, 0.5, 0.25, 0.125 µg/mL), in addition to 
negative (media only) controls. The MICs were determined as 
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the first dilution to show complete growth inhibition as 
determined by a total lack of colony formation within the test 
period. It was not possible to obtain an authentic sample of 
naturally isolated lassomycin to compare in this assay because 
the Lentzea kentuckyensis subspecies from which lassomycin 
was originally prepared is the property of NovoBiotic 
Pharmaceuticals and was unavailable. 
 
Compounds 
Fmoc-Asp(OtBu)-Ile-OMe (10). Fmoc-Asp-(OtBu)-OH (1.14 g, 
1.0 equiv, 2.77 mmol,), H-Ile-OMe (0.40 g, 1.0 equiv, 2.77 
mmol) and PyBOP® (1.44 g, 1.0 equiv, 2.77 mmol) were 
suspended in DCM (30 mL) and stirred at room temperature. 
N-Methylmorpholine (0.91 mL, 3.0 equiv, 8.31 mmol) was 
added and the reaction was stirred at room temperature for 
18 h. The crude reaction mixture was evaporated under 
reduced pressure and purified via column chromatography 
(SiO2; 98/2% hexane/EtOAc → 50/50% hexane/EtOAc) to yield 
Fmoc-Asp(OtBu)-Ile-OMe (10) as a white powder (0.934 g, 
63%), δH (700 MHz, CDCl3) 0.88–0.93 (3H, m, Ile-δCH3), 0.88–
0.93 (3H, m, Ile-γCH3), 1.15–1.23 (1H, m, Ile-γCH2), 1.38–1.44 
(1H, m, Ile-γCH2), 1.46 (9H, s, OtBu), 1.89–1.95 (1H, m, Ile-
βCH), 2.64 (1H, dd, J 17.3 and 7.3 Hz, Asp-βCH2), 2.93 (1H, dd, J 
17.3 and 4.1 Hz, Asp-βCH2), 3.71 (3H, s, CO2CH3), 4.23 (1H, t, J 
7.1 Hz, FmocCH), 4.41 (2H, d, J 7.1 Hz, FmocCH2), 4.53 (1H, dd, 
J 8.6 and 4.8 Hz, Ile-αCH), 4.58–4.63 (1H, m, Asp-αCH), 6.08 
(1H, d, J 8.2 Hz, AspNH), 7.16 (1H, d, J 8.6 Hz, IleNH), 7.31 (2H, 
t, J 7.5 Hz, FmocArH), 7.40 (2H, t, J 7.5 Hz, FmocArH), 7.59 (2H, 
d, J 7.5 Hz, FmocArH), 7.76 (2H, d, J 7.5 Hz, FmocArH); δC (176 
MHz, CDCl3) 11.6, 15.6, 25.1, 28.1, 37.6, 47.2, 50.9, 52.1, 56.9, 
67.4, 82.0, 120.1, 125.1, 127.2, 127.8, 141.4, 143.7, 143.9, 
156.0, 170.6, 171.6, 171.9; HRMS m/z (ESI) 539.2756, 
consistent with empirical formula C30H39N2O7 with an accuracy 
of 0.2 ppm (accepted as [M + H]
+
). 
Fmoc-Asp(OH)-Ile-OMe (13). Fmoc-Asp(OtBu)-Ile-OMe (10, 
0.33 g, 0.61 mmol) was treated with 20 mL of TFA solution 
(40% in DCM) for 30 min. Complete removal of the t-butyl 
group was confirmed using TLC. The reaction mixture was 
evaporated under reduced pressure to give Fmoc-Asp(OH)-Ile-
OMe (13) as a white powder (quantitative yield, 0.29 g) which 
was used without further purification. δH (700 MHz, CDCl3) 
0.86–0.91 (3H, m, Ile-δCH3), 0.86–0.91 (3H, m, Ile-γCH3), 1.11–
1.20 (1H, m, Ile-γCH2), 1.35–1.44 (1H, m, Ile-γCH2), 1.85–1.96 
(1H, m, Ile-βCH), 2.78 (1H, dd, J 17.4 and 6.4 Hz, Asp-βCH2), 
3.03 (1H, d, J 17.4 Hz, Asp-βCH2), 3.72 (3H, s, CO2CH3), 4.22 
(1H, t, J 6.6 Hz, FmocCH), 4.43 (2H, d, J 6.6 Hz, FmocCH2), 4.53 
(1H, dd, J 8.4 and 4.7 Hz, Ile-αCH), 4.60–4.69 (1H, m, Asp-αCH), 
5.97 (1H, d, J 8.0 Hz, AspNH), 7.09 (1H, d, J 8.4 Hz, IleNH), 7.31 
(2H, t, J 7.5 Hz, FmocArH), 7.40 (2H, t, J 7.5 Hz, FmocArH), 7.57 
(2H, d, J 7.5 Hz, FmocArH), 7.76 (2H, d, J 7.5 Hz, FmocArH); 
HRMS m/z (ESI) 483.2115, consistent with empirical formula 
C26H31N2O7 with an accuracy of 3.3 ppm (accepted as [M + H]
+
). 
Lassomycin (1). The dipeptide Fmoc-Asp(OH)-Ile-OMe (13) 
was coupled manually to Rink amide AM resin (0.79 mmol/g 
substitution, 0.10 mmol scale) using two 1 h couplings at RT. 
The sequence GLRRLFADQLVGRR was then built onto the 
resin-supported dipeptide via automated SPPS at room 
temperature (as described). Resin cleavage, cyclization and 
purification by high-performance liquid chromatography were 
carried out as detailed above to afford lassomycin (26 mg, 
14%), MALDI-TOF mass: found m/z 1881.1 [M + H]
+
, calcd 
1881.2 [M + H]
+
; HRMS m/z (ESI) 940.55785, consistent with 
empirical formula C83H144N30O20 with an accuracy of 0.3 ppm 
(accepted as [M + 2H]
2+
). 
Lassomycin-amide (2). Linear peptide 
GLRRLFADQLVGRRNI-amide was synthesized via automated 
SPPS at room temperature (as described) on Rink amide AM 
resin (0.79 mmol/g substitution, 0.10 mmol scale). Resin 
cleavage, cyclization and purification by high-performance 
liquid chromatography were carried out as detailed above to 
afford lassomycin-amide (4 mg, 8%), MALDI-TOF mass: found 
m/z 1866.2 [M + H]
+
, calcd 1866.2 [M + H]
+
; HRMS m/z (ESI) 
933.06000, consistent with empirical formula C82H143N31O19 
with an accuracy of 1.8 ppm (accepted as [M + 2H]
2+
). 
Lassomycin(1-9) (17). Linear peptide GLRRLFADQ-amide 
was synthesized via automated SPPS on Rink amide AM resin 
(0.79 mmol/g substitution, 0.10 mmol scale). Resin cleavage, 
cyclization and purification by high-performance liquid 
chromatography afforded lassomycin(1-9) (31 mg, 29%), 
MALDI-TOF mass: found m/z 1056.6 [M + H]
+
, calcd 1057.2 [M 
+ H]
+
; HRMS m/z (ESI) 1056.6082, consistent with empirical 
formula C47H78N17O11 with an accuracy of 1.4 ppm (accepted as 
[M + H]
+
). 
Abbreviations 
AM Aminomethyl 
ATP Adenosine triphosphate 
DCM Dichloromethane 
DIPEA N,N-Diisopropylethylamine 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
ES Electrospray 
ESI Electrospray ionization 
Fmoc Fluorenylmethyloxycarbonyl 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate 
HOAt 3H-[1,2,3]-Triazolo[4,5-b]pyridin-3-ol 
HPLC High-performance liquid chromatography 
IM Ion-mobility 
LC Liquid chromatography 
LIFT LIFT 
MALDI Matrix-assisted laser desorption/ionization 
MeCN Acetonitrile 
MIC Minimum inhibitory concentration 
MS Mass spectrometry 
NMM N-Methylmorpholine 
NMR Nuclear magnetic resonance 
Pbf 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl 
PyBOP® (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate 
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RT Room temperature 
SPPS Solid-phase peptide synthesis 
tBu tert-Butyl 
TFA Trifluoroacetic acid 
TIPS Triisopropylsilane 
TLC Thin-layer chromatography 
TOF Time of flight 
Trt Triphenylmethyl 
UPLC Ultra-performance liquid chromatography 
UV Ultraviolet 
HRMS High-resolution mass spectrometry 
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